Moving your Cell Therapy from Concept to Product

By on August 19, 2013
Ask the Expert

Ask our Expert about navigating funding and grant writing, partnering with organizations, and the regulatory process.

Hosted by the California Institute for Regenerative Medicine (CIRM)

There are an increasing number of promising new stem cell therapy applications in research and development. When these potential therapies show promise, the challenge of moving these therapies from concept to commercialization can be a daunting and confusing task. Important steps need to be followed for success including finding funding, creating effective partnerships with organizations and fostering a positive regulatory process, including IND submission. If you have questions about the best way to move your product idea forward , then please join us for a special Ask the Expert session “Moving your Cell Therapy from Concept to Product.

View Topic or Post A Question

Hosting this week’s session is Neil Littman, the Business Development Officer at the California Institute for Regenerative Medicine (CIRM): Mr. Littman is responsible for facilitating opportunities for outside investment in stem cell research in California for both CIRM-funded and non CIRM-funded programs by biopharmaceutical strategic partners, equity investors, and disease foundations.

Prior to joining CIRM in 2012, Mr. Littman was a Senior Associate in the Merchant Banking Group at Burrill & Company, a diversified global financial services firm focused on the life sciences industry based in San Francisco.  While at Burrill & Company, Mr. Littman’s responsibilities included both strategic advisory and capital raising assignments for biopharmaceutical companies throughout the U.S. and internationally.

Mr. Littman’s strategic advisory experience includes buy-side and sell-side M&A, as well as in-licensing and out-licensing of both development stage and commercial products.  Prior to joining Burrill & Company in 2009, Mr. Littman worked in the Healthcare Investment Banking group at Thomas Weisel Partners where he focused on strategic advisory assignments and public and private financings. Prior to Thomas Weisel Partners, Mr. Littman worked in the Healthcare Investment Banking group at Deutsche Bank Securities.

Mr. Littman received a Master of Science in Biotechnology with a concentration in Biotechnology Enterprise from The Johns Hopkins University, and a Bachelor of Arts in Molecular, Cellular and Development Biology from the University of Colorado Boulder in 2002.

View Topic or Post A Question

About CIRM:

CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research.  In 2012, CIRM adopted an “Industry Engagement and Commercialization Plan,” which serves as CIRM’s blueprint for continuing to support Proposition 71’s mission by engaging industry and supporting commercialization of CIRM’s funded research. You can find more information about CIRM here:

CIRM Resources:

Please take advantage of the opportunity to ask a question and participate in an important discussion about navigating your cell therapy to commercialization.

Ask the Expert

Ask the Expert is an exciting feature on the Cell Culture Dish where both industry and academic experts answer your questions. A range of topics will be covered and suggestions for future Ask the Expert sessions are welcome.